Global Ependymoma Drug Market, by Drug Type (Corticosteroids, Antiseizure Agents and Others), by Disease Type (Subependymoma, Myxopapillary Ependymoma, Anaplastic Ependymoma and Classic Ependymomas), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Online Pharmacy), and by Region (North America, Latin America, Europe, Asia-Pacific, Middle East & Africa) is estimated to be valued at US$ 143.0 Mn in 2022 and is expected to exhibit a CAGR of 4.8% during the forecast period (2022-2030), as highlighted in a new report published by Coherent Market Insights.
Key trends in market include increasing launches of research projects for ependymoma which is expected to drive the growth global ependymoma drug market over the forecast period. For instance, in August 2020, Children's Cancer and Leukaemia Group is an organization focused on childhood cancer launched a new research project aiming to develop a new, non-invasive approach to identify the different types of ependymoma brain tumours funded by Edie’s Butterfly Appeal. Edie’s Butterfly Appeal was set up in 2014 to raise funds for childhood ependymoma, a tumour that grows in the brain or spinal cord, often in very young children (children under 5 years of age).
Global Ependymoma Drug Market – Impact of Coronavirus (COVID-19) Pandemic
The COVID-19 pandemic caused major disruptions to clinical trial execution in the U.S., impacting key stakeholders across the industry. Investigative site capabilities experienced upheaval, driven by staff furloughs, social-distancing protocols, financial losses, and concerns over patient safety. Sponsors, Contract research organization (CROs), and other organizations that support drug development shifted to remote working environments. An estimated 80% of non-COVID-19 trials were stopped or interrupted as a result of the COVID-19 pandemic. An April 2020 study on the Impact of COVID-19 on Clinical Trial Sites conducted by Medidata, a life sciences software provider that supports clinical trials with a primary focus on evidence generation, suggests that investigative sites demonstrated flexibility and ingenuity in adopting new approaches in order to cope with challenges presented by the pandemic, with over half of investigative sites transitioning to virtual approaches to interact with patients. More recently, follow-up studies performed in August 2020 have identified persistent impact of COVID-19 pandemic, with over 60% reporting an average or greater level of impact on ongoing trials and initiation of new trials. Respondents specifically highlighted challenges in patient enrollment and recruitment. Recently, the U.S. Food and Drug Administration (FDA) guidance (March 2020 and updated July 2020) acknowledged that the impact of COVID-19 may require companies conducting clinical trials to consider virtual patient visits or put new processes in place of current protocols. Therefore, there are now more opportunities for using remote healthcare including conducting virtual or decentralized trials, site-less clinical trials, and use of other non-traditional approaches that do not involve in-person visits.